The intensification of anticancer activity of LFM-A13 by erythropoietin as a possible option for inhibition of breast cancer

Figures & data

Figure 2. Representative dot-plots presenting the loss of mitochondrial membrane potential (MMP) in MCF-7 (A), and MDA-MB-231 (B) cells incubated with Epo (Epo100, 100 IU/ml) and LFM-A13 (LFM100, 100 μM) for 48 h (mean ± SD; n = 3). Cells with normal MMT are shown on the left side of the plots, cells with decreased MMT on the right side of the plots.

Figure 5. Representative examples of immunohistochemistry for BTK expression in breast cancer cells.

Table 1. BTK expression in primary tumours and metastases to lymph nodes.

	BTK expression	Primary tumour
		0	1	2	3	4	Total number of cases
Lymph node metastasis	0	5	1	–	2	–	8
	1	2	1	–	2	2	7
	2	1	3	–	–	–	4
	3	–	7	1	–	–	8
	4	–	3	–	–	1	4
	Total number of cases	8	15	1	4	3	31

Data are expressed as the number of paired cases in each group. BTK expression levels in primary tumours and metastases were assigned on a 0–4+ scale, as described in Materials and Methods.

Table 2. Spearman’s rho correlation between BTK level in tumour and node metastasis and selected parameters.

Spearman’s rho	Bruton kinase in primary tumour	Bruton kinase in lymph node metastasis
Bruton kinase in primary tumour
Correlation coefficient	1	0.308
Sig. (2-tailed)	–	0.092
N	90	31
Age
Correlation coefficient	−0.036	0.225
Sig. (2-tailed)	0.739	0.224
N	89	31
G
Correlation coefficient	0.025	−0.14
Sig. (2-tailed)	0.832	0.505
N	76	25
pT
Correlation coefficient	0.056	−0.023
Sig. (2-tailed)	0.616	0.907
N	83	28
pN
Correlation coefficient	0.212	–
Sig. (2-tailed)	0.076	–
N	71	32
HER2
Correlation coefficient	−0.143	−0.216
Sig. (2-tailed)	0.181	0.235
N	89	32
Oestrogen receptors
Correlation coefficient	−0.191	0.171
Sig. (2-tailed)	0.073	0.35
N	89	32
Progesterone receptors
Correlation coefficient	−0.112	0.02
Sig. (2-tailed)	0.298	0.915
N	89	32
Ki-67
Correlation coefficient	−0.102	0.013
Sig. (2-tai)	0.66	0.974
N	21	9

Figure 6. Schematic diagram of intracellular proteins BTK and JAK2 interaction and LFM-A13 mechanism of action. EPO: erythropoietin, LFM-A13: Bruton’s tyrosine kinase inhibitor; JAK2: non-receptor tyrosine kinase; BTK: Bruton’s tyrosine kinase; Akt: protein kinase B; PIP3: phosphatidylinositol-3,4,5-triphosphate; PH: pleckstrin homology domain.